Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on October 16, 2018 in Immunotherapy
At ASCO 2018, 3 new studies that explore chemotherapy plus immunotherapy got high remarks from Sibylle Loibl, MD, PhD, including a regimen that may be a new standard of care.
Web Exclusives published on October 16, 2018 in Lynch Syndrome
The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.
Web Exclusives published on October 15, 2018 in Breast Cancer

The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.

Web Exclusives published on October 9, 2018 in Immunotherapy, Multiple Myeloma

The second-generation chimeric antigen receptor (CAR) T-cell therapy, bb2121, engineered to target B-cell maturation antigen, a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial in patients with relapsed or refractory multiple myeloma.

Web Exclusives published on September 7, 2018 in Emerging Therapies
“Both responders and those who didn’t respond to ivosidenib achieved transfusion independence. Ivosidenib was well-tolerated, and adverse events were managed with standard of care,” said Daniel A. Pollyea, MD, MS, at ASCO 2018.
Web Exclusives published on September 4, 2018 in Health Policy
FDA Commissioner Scott Gottlieb, MD, announced new steps as part of the FDA’s Drug Competition Action Plan to promote generic drug competition as a way to expand potential access to inexpensive medicines, which would be especially helpful for patients with cancer.
Web Exclusives published on August 10, 2018 in Immunotherapy
The NCCN’s first guideline for side effects from immunotherapy recognizes a new spectrum of events in patients who are receiving immune checkpoint inhibitor therapy.
Web Exclusives published on August 6, 2018 in Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy has had excellent results in late-stage leukemia and varying degrees of success in some other hematologic cancers, but thus far, solid tumors have not responded to this therapy.

In the FDA’s dynamic regulatory environment, the patient voice has been adopted and end points for clinical trials have evolved from overall survival to other efficacy measures. “Having multiple drugs is a good thing. Many are approved on nonsurvival end points, and they have transformed the diseases,” said Richard Pazdur, MD.
Web Exclusives published on May 10, 2018 in Leukemia

New results from the phase 3 QuANTUM-R trial showed that quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation.

Page 4 of 12
Results 31 - 40 of 115